8224038

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

March 18, 2022

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THIS OFFICE OF:

PATENT NUMBER: ***9,540,445***
ISSUE DATE: ***January 10, 2017***

By Authority of the
Under Secretary of Commerce for Intellectual Property
and Director of the United States Patent and Trademark Office

Curtis Goffe
Curtis Goffe
Certifying Officer

US009540445B2

(12) **United States Patent**
June et al.

(10) **Patent No.: US 9,540,445 B2**
(45) **Date of Patent: *Jan. 10, 2017**

(54) **COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER**

(71) Applicant: **The Trustees of the University of Pennsylvania**, Philadelphia, PA (US)

(72) Inventors: **Carl H. June**, Merion Station, PA (US); **Bruce L. Levine**, Cherry Hill, NJ (US); **David L. Porter**, Springfield, PA (US); **Michael D. Kalos**, Philadelphia, PA (US); **Michael C. Milone**, Cherry Hill, NJ (US)

(73) Assignee: **The Trustees of the University of Pennsylvania**, Philadelphia, PA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/997,136**

(22) Filed: **Jan. 15, 2016**

(65) **Prior Publication Data**

US 2016/0208012 A1 Jul. 21, 2016

Related U.S. Application Data

(63) Continuation of application No. 13/992,622, filed as application No. PCT/US2011/064191 on Dec. 9, 2011.

(60) Provisional application No. 61/421,470, filed on Dec. 9, 2010, provisional application No. 61/502,649, filed on Jun. 29, 2011.

(51) **Int. Cl.**

C12N 5/071	(2010.01)
C12N 5/0783	(2010.01)
C12N 5/22	(2006.01)
C07K 16/28	(2006.01)
A61K 35/17	(2015.01)
A61K 39/00	(2006.01)
A61K 39/395	(2006.01)
C12N 15/85	(2006.01)
C07K 14/705	(2006.01)
A61K 48/00	(2006.01)
C07K 14/525	(2006.01)
C07K 14/725	(2006.01)
C07K 16/30	(2006.01)
C12N 7/00	(2006.01)
A61K 38/17	(2006.01)
A61K 45/06	(2006.01)

(52) **U.S. Cl.**

CPC ***C07K 16/2896*** (2013.01); ***A61K 35/17*** (2013.01); ***A61K 38/177*** (2013.01); ***A61K 38/1774*** (2013.01); ***A61K 39/0011*** (2013.01); ***A61K 39/39558*** (2013.01); ***A61K 45/06*** (2013.01); ***A61K 48/005*** (2013.01); ***C07K 14/525*** (2013.01); ***C07K 14/7051*** (2013.01); ***C07K 14/70517*** (2013.01); ***C07K 14/70521*** (2013.01); ***C07K 14/70578*** (2013.01); ***C07K 14/70596*** (2013.01); ***C07K 16/2803*** (2013.01); ***C07K 16/30*** (2013.01); ***C07K 16/3061*** (2013.01); ***C12N 5/0636*** (2013.01); ***C12N 7/00*** (2013.01); ***C12N 15/85*** (2013.01); *A61K 2039/505* (2013.01); *A61K 2039/5156* (2013.01); *A61K 2039/5158* (2013.01); *A61K 2039/5256* (2013.01); *A61K 2039/585* (2013.01); *C07K 2317/53* (2013.01); *C07K 2317/622* (2013.01); *C07K 2317/76* (2013.01); *C07K 2317/80* (2013.01); *C07K 2319/00* (2013.01); *C07K 2319/02* (2013.01); *C07K 2319/03* (2013.01); *C07K 2319/30* (2013.01); *C07K 2319/33* (2013.01); *C07K 2319/74* (2013.01); *C12N 2501/515* (2013.01); *C12N 2510/00* (2013.01); *C12N 2740/15034* (2013.01); *C12N 2740/15043* (2013.01); *C12N 2740/15071* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,359,046	A	10/1994	Capon et al.
5,686,281	A	11/1997	Roberts
5,712,149	A	1/1998	Roberts
5,874,240	A	2/1999	Ni et al.
5,906,936	A	5/1999	Eshhar et al.
6,103,521	A	8/2000	Capon et al.
6,319,494	B1	11/2001	Capon et al.
6,355,779	B1	3/2002	Goodwin et al.
6,410,319	B1	6/2002	Raubitschek et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP	0574512 B1	2/2003
EP	1226244	7/2004

(Continued)

OTHER PUBLICATIONS

A NCBI Direct Submission NP 000725 dated Nov. 21, 2010.

(Continued)

Primary Examiner — Michael Burkhart

(74) *Attorney, Agent, or Firm* — Saul Ewing LLP; Kathryn Doyle

(57) **ABSTRACT**

The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.

30 Claims, 26 Drawing Sheets

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,569,997	B1	5/2003	Kwon	
7,049,136	B2	5/2006	Seed et al.	
7,052,906	B1	5/2006	Lawson et al.	
7,070,995	B2	7/2006	Jensen	
7,265,209	B2	9/2007	Jensen	
7,319,143	B2	1/2008	Gross et al.	
7,320,787	B2	1/2008	Seed et al.	
7,402,431	B2	7/2008	Har-Noy	
7,446,190	B2	11/2008	Sadelain et al.	
7,446,191	B2	11/2008	Jensen	
7,514,537	B2	4/2009	Jensen	
7,741,465	B1	6/2010	Esshar et al.	
7,994,298	B2	8/2011	Zhang et al.	
8,211,422	B2	7/2012	Esshar et al.	
8,252,914	B2	8/2012	Zhang et al.	
8,389,282	B2	3/2013	Sadelain et al.	
8,399,645	B2	3/2013	Campana et al.	
8,465,743	B2	6/2013	Rosenberg et al.	
2003/0060444	A1	3/2003	Finney et al.	
2003/0077249	A1	4/2003	Bebbington et al.	
2003/0148982	A1	8/2003	Brenner et al.	
2004/0038886	A1	2/2004	Finney et al.	
2004/0043401	A1	3/2004	Sadelain et al.	
2005/0113564	A1	5/2005	Campana et al.	
2005/0129671	A1	6/2005	Cooper et al.	
2008/0131415	A1	6/2008	Riddell et al.	
2009/0257994	A1	10/2009	Jensen	
2010/0233200	A1	9/2010	Medin	
2011/0052554	A1	3/2011	Zakrzewski et al.	
2012/0148552	A1	6/2012	Jensen	
2013/0071414	A1	3/2013	Dotti et al.	
2013/0149337	A1	6/2013	Cooper et al.	
2016/0208012	A1*	7/2016	June	A61K 35/17

FOREIGN PATENT DOCUMENTS

EP	871495	6/2005
JP	2003-517301	5/2003
JP	2004-529636	9/2004
WO	WO92/15322	9/1992
WO	WO/95/30014	11/1995
WO	WO96/23814	8/1996
WO	WO96/24671	8/1996
WO	WO/97/015669	5/1997
WO	WO/97/23613	7/1997
WO	WO98/18809	5/1998
WO	WO99/00494	1/1999
WO	WO99/57268	11/1999
WO	WO/00/14257	3/2000
WO	WO 01/34843	5/2001
WO	WO/02/33101	4/2002
WO	WO 02/077029	10/2002
WO	WO/02/077029	10/2002
WO	WO/02/088334	11/2002
WO	WO2005/019429	3/2005
WO	WO 2005/044996	5/2005
WO	WO2006/060878	6/2006
WO	WO2008/045437	4/2008
WO	WO2009/091826	7/2009
WO	WO/2010/025177	3/2010
WO	WO/2010/085660	7/2010
WO	WO2011/059836	5/2011
WO	WO2012/033885	3/2012
WO	WO2012/058460	5/2012
WO	WO2012/082841	6/2012
WO	WO2012/127464	9/2012
WO	WO2012/135854	10/2012
WO	WO2012/138858	10/2012
WO	WO2013/033626	3/2013
WO	WO2013/040371	3/2013
WO	WO2013/059593	4/2013

OTHER PUBLICATIONS

A NCBI Direct Submission NP 932170.1 dated Nov. 21, 2010.

Baeksgaard et al., "Acute tumor lysis syndrome in solid tumors—a case report and review of the literature." 2003, Cancer Chemother Pharmacol., 51:187-92.

Bondanza et al., "Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes." 2006, Blood 107:1828-1836.

Brentjens et al., "Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15." 2003, Nature Medicine, 9(3): 279-286.

Brentjens et al., "Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts." 2007, Clin Cancer Res 13:5426-5435.

Brentjens et al., "Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias." 2011 Blood 118(18):4817-4828.

Brentjens et al., "Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial." 2010, Mol Ther, 18: 666-8.

Brentjens, et al. "A Phase I Trial for the Treatment of Chemo-refractory Chronic Lymphocytic Leukemia with CD19-Targeted Autologous T Cells." Mol. Therapy, 2008, p. S15, vol. 16, Suppl 1.

Brocker and Karjalainen, "Signals through T cell receptor-ζ chain alone are insufficient to prime resting T lymphocytes." 1995, J. Exp. Med., 181:1653-1659.

Call, et al., "The T cell receptor: critical role of the membrane environment in receptor assembly and function." 2005, Annu Rev Immunol. 2005, 23:101-125.

Campana et al., "T-Cell Immunotherapy for B-Lineage Acute Lymphoblastic Leukemia Using Chimeric Antigen Receptors That Deliver 4-1BB-Mediated Costimulatory Signals" 2003 Blood 102(11); abstract #223.

Carpenito et al., "Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains." 2009, Proc Natl Acad Sci U S A 106:3360-3365.

Davila et al., "B Cell Aplasia in a Patient with Relapsed B Cell Acute Lymphoblastic Leukemia Following Re-Induction and Consolidation with Autologous T Cells Genetically Targeted to the CD19 Antigen." 2010 ASH Meeting Abstract No. 3268, presented Dec. 6, 2010 (poster abstract).

Davila et al., "T Cells Genetically Targeted to CD19 Eradicate B-All in a Novel Syngeneic Mouse Disease Model." 2010 ASH Meeting Abstract No. 171, presented Dec. 6, 2010 (poster abstract).

Dohner et al., "p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias." 1995, Blood, 85: 1580-9.

Dropulic et al., "Gene-based immunotherapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome." 2006, Human Gene Therapy, 17: 577-88.

Dull et al., "A third-generation lentivirus vector with a conditional packaging system." 1998, J Virol, 72: 8463-71.

Eshhar et al., "Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the Y or ζ subunits of the immunoglobulin and T-cell receptors." 1993, Proc Natl Acad Sci USA 90:720-724.

Finney et al., "Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 (4-1BB) in series with signals from the TCR zeta chain." 2004, J. Immunol 172:104-113.

Finney et al., "Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product." 1998, J Immunol 161:2791-2797.

Friedmann-Morvinski et al., "Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation." 2005, Blood 105:3087-3093.

Geiger and Jyothi, "Development and application of receptor-modified T lymphocytes for adoptive immunotherapy." 2001, Transfusion Medicine Reviews, 15(1): 21-34.

(56) **References Cited**

OTHER PUBLICATIONS

Geiger et al., "Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes," 2001, Blood 98(8):2364-71.

Gilham et al., "Primary Polyclonal Human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3ζ- based chimeric immune receptors." 2001, J. Immunology, 25(2): 139-151.

Gong et al., "Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen." 1999, Neoplasia, 1(2): 123-127.

Gribben et al., "Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia." 2011, Biol Blood Marrow Transplant, 17: Suppl:S63-S70.

Griffin et al., "Development and application of surface-linked single chain antibodies against T-cell antigens." 2001, J. Immunological Methods, 248: 77-90.

Gross and Eshhar, 1992, "Endowing T cells with antibody specificity using chimeric T cell receptors." 1992, FASEB J. 6: 3370-3378.

Hallek et al., "Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the InternationalWorkshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute—Working Group 1996 guidelines." 2008, Blood 111(12):5446-5456.

Hekele et al., "Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:zeta-chimera." 1996, Int J Cancer 68:232-238.

Ho et al., "Adoptive Immunotherapy: Engineering T cell responses as biological weapons for tumor mass destruction." 2003, Cancer Cell 3:431-437.

Hollyman et al., "Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy." J. Immunother., 2009, pp. 169-180, vol. 32, No. 2.

Homback et al., "The Recombinant T Cell Receptor Strategy: Insights into Structure and Function of Recombinant Immunoreceptors on the Way Towards an Optimal Receptor Design for Cellular Immunotherapy," 2002 Current Gene Therapy 2:211-226.

Imai et al., "Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia." 2004, Leukemia 18(4):676-684.

Imai et al., 2005, Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells, Blood, 106:376-383.

International Search Report for PCT/US2011/064191 dated May 1, 2012.

Irving & Weiss, "The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways." 1991, Cell 64:891-901.

Jena et al., "Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor." 2010, Blood, 116: 1035-44.

Jensen et al., "Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans." 2010 Biol Blood Marrow Transplant 16:1245-1256.

Johnson et al., "Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen." 2009, Blood, 114: 535-46.

June et al., "Engineering lymphocyte subsets: tools, trials and tribulations." 2009, Nat Rev Immunol, 9: 704-16.

Kalos, et al., "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia," 2011, Sci Transl Med 3(95):95ra73.

Kershaw et al., "A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer." 2006, Clin Cancer Res 12:6106-6115.

Kim et al., "Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses." 1998, Eur J Immunol 28:881-890.

Kochenderfer et al., "Construction and Pre-clinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor." 2009, J Immunother 32(7)689-702.

Kochenderfer, et al., "A Phase I Clinical Trial of Treatment of B-Cell Malignancies with Autologous Anti-CD19-CAR-Transduced T Cells." 2010 ASH Meeting Abstract No. 2865, presented Dec. 5, 2010 (poster abstract).

Kochenderfer, et al., "Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells." 2010, Blood, 116(9)3875-3886.

Kochenderfer, et al., "Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically-engineered to recognize CD19." 2010, Blood 116:4099-4102.

Kochenderfer, et al., "Novel Antigen-Specific Expansion of T Cells Transduced with a CD19 Chimeric Antigen Receptor." 2010 ASH Meeting Abstract No. 3262, presented Dec. 6, 2010 (poster abstract).

Kohn, et al., "CARs on track in the clinic." 2011, Molecular Ther 19(3):432-438.

Krause et al., "Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes." 1998, J. Exp. Med., 188(4): 619-626.

Lamanna et al., "Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia." 2006, J Clin Oncol, 24: 1575-81.

Lamers et al., "Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience." 2006, J Clin Oncol 24:e20-e22.

Laport et al., "Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation." 2003, Blood 102: 2004-2013.

Lee et al., "In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy." 2011, Cancer Res 71:2871-2881.

Letourneur & Klausner, "T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins." 1991, Proc Natl Acad Sci U S A 88:8905-8909.

Levine et al., "Gene transfer in humans using a conditionally replicating lentiviral vector." 2006, Proc Natl Acad Sci U S A 103:17372-17377.

Macallan et al., "Measurement and modeling of human T cell kinetics." 2003, Eur J Immunol, 33: 2316-26.

Maher et al., "Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor." 2002, Nat Biotechnol 20(1):70-5.

McGuinness, et al., "Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor." 1999, Hum.Gene Ther 10:165-173.

Milone et al., "Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo." 2009, Mol Ther 17(8):1453-64.

Molina, "A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma." 2008, Ann Rev Med, 59: 237-50.

Morgan et al., "Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2." 2010, Mol Ther, 18: 843-51.

Moritz & Groner, "A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity," 1995, Gene Therapy, 2:539-546.

Moritz et al., "Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells" 1994, Proc. Natl. Acad. Sci. 91:4318-4322.

Naldini et al., "In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector." 1996, Science, 272: 263-7.

(56) **References Cited**

OTHER PUBLICATIONS

Nicholson, et al., "Constructions and Characterization of a Functional CD19 Specific Single Chain Fv Fragment for Immunotherapy of B Lineage Leukemia and Lymphoma." Mol. Immunol., 1997, pp. 1157-1165, vol. 34, No. 16-17.

Ochoa et al., Immune Defects in T Cells From Cancer Patients, Parallels in Infectious Diseases, from: Cancer Immunotherapy at the Crossroads: how tumors evade immunity and what can be done (current clinical oncology), edited by James H. Finke, Ronald M. Bukowski,, 2004 edition.

Park and Brentjens, "Adoptive Immunotherapy for B-cell Malignancies with Autologous chimeric Antigen Receptor Modified Tumor Targeted T Cells." 2010, Discov Med 9(47):277-288.

Park et al., "Adoptive transfer of chimeric antigen receptor redirected cytolytic T lymphocyte clones in patients with neuroblastoma." 2007, Mol Ther 15:825-833.

Patel et al., "Impact of chimeric immune receptor extracellular protein domains on T cell function." 1998, Gene Therapy, 6: 412-419.

Porter et al, "A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation." 2006, Blood, 107:1325-31.

Porter et al., Chimeric Antigen Receptor Therapy for B-cell Malignancies. 2011, J Cancer 2:331-332.

Porter, "Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia." 2011 New England J Med 365(8):725-733.

Pule et al., "Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma." 2008, Nat Med 14:1264-1270.

Rapoport et al., "Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer." 2005, Nat Med 11:1230-1237.

Roederer, "T-cell dynamics of immunodeficiency." 1995, Nat Med, 1: 621-7.

Romeo & Seed, "Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides." 1991,Cell 64:1037-1046.

Sabbagh et al., "TNF family ligands define niches for T cell memory." 2007, Trends Immunol 28:333-339.

Sadelain et al., "Targeting tumours with genetically enhanced T lymphocytes." 2003,Nat Rev Cancer 3(1):35-45.

Sadelain et al., "The promise and potential pitfalls of chimeric antigen receptors." 2009, Curr Opin Immunol, 21: 215-23.

Savoldo et al., "CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients." 2011, J Clin Invest 121(5):1822-6.

Sebestyen, et al., "Human TCR that incorporate CD3zeta induce highly preferred pairing between TCRalpha and beta chains following gene transfer." 2008, J Immunol. 2008, 180(11):7736-46.

Song, et al. "CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo." 2011 Blood 119:696-706.

Sorror et al., "Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia." 2008, Blood, 111: 446-52.

Tammana Syam et al., "4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies." 2010 Human Gene Therapy 21:75-86.

Till et al., "Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells." 2008, Blood, 112, 2261-2271.

Uckun, et al., "Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins." 1988, Blood, 71:13-29.

Vinay and Kwon, "Role of 4-1BB in immune responses." 1998, Seminars in Immunology, 10:481-489.

Willemsen et al., "Genetic Engineering of T Cell Specificity for Immunotherapy of Cancer." 2003,Human Immunology, 64: 56-68.

Zufferey et al., "Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo." 1997, Nature Biotechnology 15:871-875.

Chinese Patent Application No. 201180067173.X—Office Action dated Oct. 22, 2014.

Chinese Patent Application No. 201180067173.X—Second Office Action dated Jul. 10, 2015.

Colombia Patent Application No. 13-137636—Colombian resolution No. 8176 dated Feb. 27, 2015.

Colombia Patent Application No. 13-137636—English translation of Office Action of Sep. 5, 2014.

Cuba Patent Application No. 2013/0079 Office Action of Apr. 1, 2014.

Cuba Patent Application No. 2013/0079 Office Action of Oct. 28, 2014.

Eurasian Region Patent Application No. 201390847/28 Office Action dated Mar. 11, 2015.

European Patent Appl 11846757.0 European Search Report of Dec. 2, 2014.

European Patent Application No. 11846757.0—Office Action dated Aug. 17, 2015.

Guatemala Patent Application No. A-2013-150—English translation of Observer's comments of Sep. 17, 2014.

Japanese Patent Application No. 2013-543380—Office Action dated Oct. 15, 2015.

Mexican Patent Application No. MX/a/2013/006570—Office Action dated Oct. 9, 2015.

New Zealand Patent Application No. 612512—First Exam Report of Nov. 20, 2013.

Thailand Patent Application No. 1301003120—Office Action of Jul. 2014.

U.S. Appl. No. 14/107,302—Final Office Action of Mar. 31, 2015.

U.S. Appl. No. 14/107,302—non-final Office Action of Sep. 30, 2014.

U.S. Appl. No. 14/567,426—non-final Office Action of Jan. 16, 2015.

U.S. Appl. No. 14/568,195—non-final Office Action of Jan. 30, 2015.

U.S. Appl. No. 14/568,569—non-final Office Action of Jan. 15, 2015.

U.S. Appl. No. 13/992,622—non-final Office Action of Jun. 19, 2015.

U.S. Appl. No. 13/992,622—Final Office Action of Jan. 5, 2016.

U.S. Appl. No. 14/465,952—non-final Office Action of Nov. 20, 2014.

U.S. Appl. No. 13/938,923—Final Office Action mailed Mar. 28, 2014.

U.S. Appl. No. 13/938,923—Final Office Action mailed Oct. 8, 2014.

U.S. Appl. No. 13/938,923—non-final Office Action of Sep. 19, 2013.

U.S. Appl. No. 13/938,947—Final Office Action of Sep. 11, 2014.

U.S. Appl. No. 13/938,947—non-final Office Action of Dec. 16, 2013.

U.S. Appl. No. 14/466,096—non-final Office Action of Oct. 8, 2014.

Colombian Patent Application No. 15-80428—Office Action issued Dec. 23, 2015.

Colombian Patent Application No.—No. 13-137536—Office Action issued Nov. 23, 2015.

Eurasian Patent Application No. 201390847—Office Action issued Feb. 14, 2016.

U.S. Appl. No. 13/992,622—Final Office Action issued Jan. 5, 2016.

U.S. Appl. No. 14/996,953—non-final Office Action issued Feb. 22, 2016.

"Genetically Engineered Lymphocyte Therapy in Treating Patients with B-Cell Leukemia or Lymphoma That is Resistant or Refractory to Chemotherapy" ClinicalTrials.gov Identifier NCT01029366; Retrieved from the internet on Jan. 29, 2016. Found at https://www.clinicaltrials.gov/ct2/show/NCT01029366?term=NCT01029366&rank=1.

"Pilot Study for Patients with Chemotherapy Resistant or Refractory CD19 Leukemia and Lymphoma (CART-19)" ClinicalTrials.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.